Wednesday, April 09, 2025 4:06:35 PM
My intent was to invest in a company that had an anti-HIV monoclonal antibody. That is why I invested in BioClonetics and stayed invested after the BioClonetics-ENZC merger. What due diligence was going to tell me that Chandra and the Cotropias would take the antibody and leave ENZC with the antibody?
And the antibody has not yet been shown to be a failure. Chandra and the Cotropias can still test that antibody on animals and humans, and that antibody can still prove to be profitable.
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
